Navigation Links
Evotec Starts Phase II in Smoking Cessation with EVT 302
Date:2/28/2008

ination transaction involving Evotec and Renovis, including future financial and operating results, the combined company's plans, objectives, expectations and intentions, the anticipated timing and results of the combined company's clinical and preclinical programs, and other statements that are not historical facts. Evotec cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. These include risks and uncertainties relating to: the ability to obtain regulatory approvals of the transaction on the proposed terms and schedule; the parties' ability to complete the transaction because conditions to the closing of the transaction may not be satisfied; the failure to successfully integrate the businesses; unexpected costs or liabilities resulting from the transaction; the risk that synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; general worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations. The risks included above are not exhaustive.

Contact:

Evotec AG

Anne Hennecke

SVP, Investor Relations & Corporate Communications

Phone: +49(0)40-56081-286

Fax: +49(0)40-56081-333

E-Mail: anne.hennecke@evotec.com


'/>"/>
SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. Evotec Reports Third Quarter 2007 Results
6. Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board
7. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
8. Evotec to Present at the BIO CEO & Investor Conference 2008 in New York
9. Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million
10. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 VetStem Biopharma, proudly announces ... Jeffrey Schaffer, DVM, as Director of Veterinary Professional ... of experience in the veterinary regenerative medicine field ... our veterinarian lead organization”. Dr. Alexis Nahama, ... will be responsible for all technical activities in ...
(Date:5/5/2015)... , May 5, 2015 Psyche Systems ... alliance which offers a first-of-its-kind platform that helps labs ... to lab results, transforms the way patients engage with ... Luminate Health provides a HIPAA-compliant digital platform ... access, manage, and understand their lab results, and uniquely ...
(Date:5/5/2015)... DIEGO , May 5, 2015  Renova™ ... for congestive heart failure and other chronic diseases, ... an independent analysis designed to reflect the healthcare ... time. This model will be used to characterize ... CHF, could have on those groups of patients ...
(Date:5/5/2015)... May 5, 2015  A group of biotechnology executives ... Coma Research Institute, a non-profit organization dedicated to providing ... suffering from disorders of consciousness.  ...   ... in which no voluntary actions can be initiated by ...
Breaking Biology Technology:Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5
... Corporation,s (NYSE AMEX LLC: ETC) ("ETC" or the ... of Mr. Ray Wyngarden as Western Regional Sales ... expanding market awareness of the BARA-MED(R) XD Monoplace ... the western portion of the United States.Mr. Wyngarden,s ...
... Group at Frost & Sullivan is ... Presentation on the Global Active Pharmaceutical Ingredients (API) ... 2009, at 3 p.m. GMT.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )The ... is currently witnessing a rapid shift towards biopharmaceuticals. ...
... Traditional Cardiac Safety Approaches , ... ... a leading innovator in advanced cardiac safety biomarkers and automated ... of pharmaceutical companies, biotechnology companies and industry consultants. When ...
Cached Biology Technology:Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff 2Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff 3The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics 2The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics 3Avoiding False Positives Key Priority in Cardiac Safety Studies 2
(Date:4/9/2015)... JOSE, Calif. , April 9, 2015 ... human interface solutions, announced today that it will report ... on Thursday, April 23, 2015, after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... is present when it comes to human evolution. ... that concludes "archaic" humans, somewhere in Africa during the ... and transferred small amounts of genetic material to their ... geneticist Michael Hammer and a team of evolutionary biologists, ...
... from custom DNA molecules could be used to personalize cancer ... an international team of researchers led by scientists at UC ... The new nanosensors can quickly detect a broad class of ... switches of life. The research is described in an article ...
... New research from the Keck School of Medicine of ... damage to the liver caused by drugs like acetaminophen ... Tylenol, helps relieve pain and reduce fever. The over-the-counter ... flu remedies as well as prescription painkillers like Percocet ...
Cached Biology News:Evolution's past is modern human's present 2Evolution's past is modern human's present 3Nanosensors made from DNA may light path to new cancer tests and drugs 2Nanosensors made from DNA may light path to new cancer tests and drugs 3USC scientists identify key protein linked to acute liver failure 2
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... offers SNP loci identification through targeting ... assay design, intensive assay validation/optimization, high ... Corriell or customer-supplied samples and sequence ... provides for rapid and highly accurate ...
... 6 delivers enhanced statistics and statistical ... quality improvement managers. As an accepted ... 6 simplifies statistics for novice users ... by experts. It offers a powerful ...
... These 384-Well Microarray plates are ideal for use ... volume liquid handling applications (down to 5µl). These ... cylindrical well design. Features ... formats available 70µl well volume (cylindrical well), ...
Biology Products: